EMP3 is upregulated upon epithelial–mesenchymal transition and contributes to EGFR–tyrosine kinase inhibitor resistance in lung adenocarcinoma
Abstract Tyrosine kinase inhibitors (TKIs) are a class of therapies used to target specific genetic mutations such as epidermal growth factor receptor (EGFR) mutations in cancer treatment. This study investigates the function of epithelial membrane protein 3 (EMP3) in EGFR–TKI resistance in lung ade...
Saved in:
| Main Authors: | Chunyan Wang, Mengting Xiong, Yifei Zhu, Kun Li, Jian Ni |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-025-02894-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of expression profiles and transcription factors during EGFR‐TKI acquired resistance in LUAD
by: Lili Feng, et al.
Published: (2024-12-01) -
Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01) -
Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
by: E. V. Levchenko, et al.
Published: (2023-02-01) -
Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
by: Jia-Jun Wu, MD, et al.
Published: (2025-06-01) -
Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)